• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去追逐瀑布吧:与抑制剂结合的烯酰还原酶(FabI)稳定四聚体结构并打开水通道。

Do Go Chasing Waterfalls: Enoyl Reductase (FabI) in Complex with Inhibitors Stabilizes the Tetrameric Structure and Opens Water Channels.

机构信息

Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais (UFMG), 31270-901 Belo Horizonte, Minas Gerais, Brazil.

Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.

出版信息

J Chem Inf Model. 2022 Nov 28;62(22):5746-5761. doi: 10.1021/acs.jcim.2c01178. Epub 2022 Nov 7.

DOI:10.1021/acs.jcim.2c01178
PMID:36343333
Abstract

The enzyme enoyl-ACP reductase (FabI) is the limiting step of the membrane's fatty acid biosynthesis in bacteria and a druggable target for novel antibacterial agents. The FabI active form is a homotetramer, which displays the highest affinity to inhibitors. Herein, molecular dynamics studies were carried out using the structure of FabI in complex with known inhibitors to investigate their effects on tetramerization. Our results suggest that multimerization is essential for the integrity of the catalytic site and that inhibitor binding enables the multimerization by stabilizing the substrate binding loop (SBL, L:195-200) coupled with changes in the H4/5 (QR interface). We also observed that AFN-1252 (naphtpyridinone derivative) promotes unique conformational changes affecting monomer-monomer interfaces. These changes are induced by AFN-1252 interaction with key residues in the binding sites (Ala95, Tyr146, and Tyr156). In addition, the analysis of water trajectories indicated that AFN-1252 complexes allow more water molecules to enter the binding site than triclosan and MUT056399 complexes. FabI-AFN-1252 simulations show accumulation of water molecules near the Tyr146/147 pocket, which can become a hotspot to the design of novel FabI inhibitors.

摘要

烯酰基辅酶 A 还原酶(FabI)是细菌细胞膜脂肪酸生物合成的限速酶,也是新型抗菌药物的潜在靶标。FabI 的活性形式是同源四聚体,对抑制剂具有最高的亲和力。本文使用与已知抑制剂结合的 FabI 结构进行了分子动力学研究,以研究它们对四聚体化的影响。我们的研究结果表明,多聚化对于催化位点的完整性至关重要,抑制剂结合通过稳定底物结合环(SBL,L:195-200)并与 H4/5(QR 界面)的变化相结合,从而能够促进多聚化。我们还观察到 AFN-1252(萘吡啶酮衍生物)促进了影响单体-单体界面的独特构象变化。这些变化是由 AFN-1252 与结合位点中的关键残基(Ala95、Tyr146 和 Tyr156)相互作用引起的。此外,对水轨迹的分析表明,AFN-1252 复合物比三氯生和 MUT056399 复合物允许更多的水分子进入结合位点。FabI-AFN-1252 模拟表明,水分子在 Tyr146/147 口袋附近积聚,这可能成为设计新型 FabI 抑制剂的热点。

相似文献

1
Do Go Chasing Waterfalls: Enoyl Reductase (FabI) in Complex with Inhibitors Stabilizes the Tetrameric Structure and Opens Water Channels.去追逐瀑布吧:与抑制剂结合的烯酰还原酶(FabI)稳定四聚体结构并打开水通道。
J Chem Inf Model. 2022 Nov 28;62(22):5746-5761. doi: 10.1021/acs.jcim.2c01178. Epub 2022 Nov 7.
2
Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).金黄色葡萄球菌烯酰基辅酶 A 还原酶(FabI)的错义突变导致对 AFN-1252 的耐药性。
J Biol Chem. 2013 Dec 20;288(51):36261-71. doi: 10.1074/jbc.M113.512905. Epub 2013 Nov 4.
3
Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.霍乱弧菌FabV定义了一种新型的烯酰-酰基载体蛋白还原酶。
J Biol Chem. 2008 Jan 18;283(3):1308-1316. doi: 10.1074/jbc.M708171200. Epub 2007 Nov 21.
4
AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.AFN-1252是一种来自类鼻疽伯克霍尔德菌的烯酰-ACP还原酶的强效抑制剂——晶体结构、作用模式及生物活性。
Protein Sci. 2015 May;24(5):832-40. doi: 10.1002/pro.2655. Epub 2015 Apr 2.
5
Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.基于配体和结构的大肠杆菌 FabI 抑制剂三氯生衍生物:从化学相似性到蛋白质动力学影响。
ChemMedChem. 2019 Dec 4;14(23):1995-2004. doi: 10.1002/cmdc.201900415. Epub 2019 Nov 7.
6
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.三氯生对细菌烯酰还原酶FabI的抑制作用:三氯生类似物对FabI抑制作用的结构-反应性分析
J Med Chem. 2004 Jan 29;47(3):509-18. doi: 10.1021/jm030182i.
7
Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan.与NAD(+)和三氯生结合的土拉弗朗西斯菌烯酰-酰基载体蛋白还原酶(FabI)的结构
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Nov 1;66(Pt 11):1436-40. doi: 10.1107/S1744309110039862. Epub 2010 Oct 27.
8
The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.大肠杆菌的烯酰-[酰基载体蛋白]还原酶(FabI)催化脂肪酸生物合成中的一个关键调节步骤,它接受NADH和NADPH作为辅因子,并受到棕榈酰辅酶A的抑制。
Eur J Biochem. 1996 Dec 15;242(3):689-94. doi: 10.1111/j.1432-1033.1996.0689r.x.
9
Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.铜绿假单胞菌烯酰-酰基载体蛋白还原酶(FabI)的特性:抗菌剂三氯生的作用靶点及其在酰化高丝氨酸内酯合成中的作用
J Bacteriol. 1999 Sep;181(17):5489-97. doi: 10.1128/JB.181.17.5489-5497.1999.
10
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.食品级抗菌剂黄樟素靶向大肠杆菌中的烯酰基辅酶 A 还原酶(FabI)。
Bioorg Med Chem Lett. 2020 Dec 15;30(24):127651. doi: 10.1016/j.bmcl.2020.127651. Epub 2020 Oct 29.

引用本文的文献

1
The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo.杀菌性FabI抑制剂Debio 1453可在体内清除耐抗生素淋病奈瑟菌感染。
Nat Commun. 2025 Sep 18;16(1):8309. doi: 10.1038/s41467-025-63508-w.
2
Isolation and Characterization of the Growth Hormone (ag-GH) cDNA and Three-Dimensional Modeling of This Hormone in Comparison with the Human Hormone (hGH).生长激素(ag-GH)cDNA 的分离与鉴定,以及与人生长激素(hGH)的三维建模比较。
Biomolecules. 2023 Jan 12;13(1):158. doi: 10.3390/biom13010158.